Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

In a significant advancement for Parkinson’s Disease (PD) therapy, researchers have developed a targeted nano formulation ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...